Simões Ricardo, Ferreira Amanda Cambraia, Silva Luciana Maria, Sabino Adriano de Paula, Carvalho Maria das Graças, Gomes Karina Braga
Department of Internal Medicine, Faculty of Medical Sciences of Minas Gerais, Belo Horizonte 30130-100, MG, Brazil.
Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
Diagnostics (Basel). 2023 Apr 26;13(9):1552. doi: 10.3390/diagnostics13091552.
Breast cancer is the most common cancer and the most frequent cause of death in women. Doxorubicin, an anthracycline, is an important drug due to its efficacy in treating solid cancers, especially breast cancer. However, this drug is often responsible for cardiotoxicity that may affect more than 25% of patients. This study aimed to evaluate the red cell distribution width (RDW) in women with breast cancer to monitor adverse events associated with the use of doxorubicin. A prospective study of 80 women with breast malignancy undergoing neoadjuvant doxorubicin-based chemotherapy was conducted. The patients were evaluated at baseline (T0), just after the last cycle of chemotherapy with doxorubicin (T1), and 1 year after the treatment (T2). There was a significant increase over the time points for the RDW ( < 0.001). There was a negative correlation between the RDW and C-reactive protein (CRP) levels at T1. The RDW did not show a significant difference between the groups classified according to cardiotoxicity. Based on these results, the RDW is a cost-effective test that shows a relationship with the doxorubicin response, but not with cardiotoxicity. It is a potential biomarker to evaluate patients with breast cancer after they receive chemotherapy with doxorubicin.
乳腺癌是女性中最常见的癌症，也是最常见的死因。阿霉素作为一种蒽环类药物，因其对实体癌尤其是乳腺癌的治疗效果而成为一种重要药物。然而，这种药物常导致心脏毒性，可能影响超过25%的患者。本研究旨在评估乳腺癌女性患者的红细胞分布宽度（RDW），以监测与使用阿霉素相关的不良事件。对80例接受基于阿霉素的新辅助化疗的乳腺恶性肿瘤女性患者进行了一项前瞻性研究。在基线期（T0）、阿霉素化疗最后一个周期结束后（T1）以及治疗后1年（T2）对患者进行评估。RDW在各时间点有显著增加（<0.001）。在T1时，RDW与C反应蛋白（CRP）水平呈负相关。根据心脏毒性分类的各组之间，RDW没有显示出显著差异。基于这些结果，RDW是一种具有成本效益的检测方法，它显示出与阿霉素反应有关，但与心脏毒性无关。它是评估乳腺癌患者接受阿霉素化疗后的一种潜在生物标志物。
